PUMA® - PUMA releases preliminary results for the fourth quarter and financial year 2021
PUMA® - PUMA releases preliminary results for the fourth quarter and financial year 2021
PUMA® PUMA Investor Relations | clube.zeros.eco
PUMA® - PUMA Investor Relations
PUMA® - Annual General Meeting
PUMA® - Annual General Meeting
Le azioni Puma torneranno a ruggire? - Word2Invest
PUMA® - PUMA achieves another record Quarter in Sales and EBIT despite Geopolitical Tensions and Lockdown Measures
PUMA® - Financial News
PUMA® - PUMA Investor Relations
PUMA® - Financial News
PUMA® - Corporate Governance
PUMA® - Investor Presentations
PUMA® - Annual General Meeting
PUMA announced mid-term business outlook at successful Investor's event in London - PUMA CATch up
PUMA® - Financial News
PUMA® - PUMA Investor Relations
PUMA® - Share
PUMA® - Corporate Governance
PUMA® - Financial Reports
PUMA® - Financial News
PUMA SE (@PUMAGroup) / Twitter
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire